05-May-2022 09:24 AM
Shares in Hikma Pharmaceuticals PLC fell early Thursday, after the drugmaker downgraded guidance for its Generics business due to the delayed launch of a generic of the Xyrem treatment for narcolepsy.
Hikma shares were down 9.9% at 1,670.00 pen
29-Apr-2022 05:44 PM
Hikma Pharmaceuticals PLC - London-based generic drugmaker - Confirms that it has not entered into any transaction with Opiant Pharmaceutical UK, following a PR Newswire announcement issued on Friday. The release said Opiant and Hikma entered into a co
29-Apr-2022 09:09 AM
Hikma Pharmaceuticals PLC said on Friday that both its Injectables and Branded businesses have performed well at the start of the year but noted its Generics business has experienced some headwinds.
The London-based pharmaceutical company expla
21-Apr-2022 02:37 PM
Hikma Pharmaceuticals PLC - London-based generic drugmaker - Completes acquisition of Custopharm Inc from Water Street Healthcare Partners, following approval from the US Federal Trade Commission. Back in September, Hikma agreed to buy the California-b
20-Apr-2022 09:16 AM
Hikma Pharmaceuticals PLC - London-based generic drugmaker - Receives preliminary approval from the US Federal Trade Commission for its planned acquisition of Custopharm Inc. Back in September, Hikma agreed to buy the California, US-based generic injec
25-Feb-2022 09:40 AM
Hikma Pharmaceuticals PLC - London-based generic drugmaker - Instructs Citigroup Global Markets Ltd, part of Citigroup Inc, to conduct the USD150 million first tranche of the USD300 million share buyback that it announced on Thursday. The initial phase
24-Feb-2022 10:31 AM
(Alliance News) - Hikma Pharmaceutical PLC on Thursday reported full-year revenue growth on a "strong" performance by its three business segments and lifted its shareholder payout.
Shares were trading 7.7% lower at 1,857.54 pen
30-Apr-2021 07:43 AM
Pharmaceuticals group Hikma Pharmaceuticals forecast its generics business to generate revenue toward the top end of guidance following a 'good' start to the new year that was in line with its expectations.
Full year generics revenue was now e
25-Feb-2021 08:16 AM
Pharmaceutical company Hikma Pharmaceuticals reported a rise in profit led by growth in its injectables business.
For the year ended 31 December 2020, pre-tax profit rose to $558 million from $491 million last year and revenue to rise 6% to $2.34 bill
05-Nov-2020 08:05 AM
Hikma Pharmaceuticals lifted its full-year guidance on revenue for its generics segment following stronger-than-expected performance in the year to date.
Revenue for generics was lifted to a range of $720 million to $740 million, from previous guidance r
04-Sep-2020 08:20 AM
Barclays Capital today upgrades its investment rating on Hikma Pharmaceuticals PLC (LON:HIK) to overweight (from equal weight) and raised its price target to 2800p (from 2350p).
Story provided by StockMarketWire.com
Broker Forecasts data provided by www
14-Aug-2020 09:20 AM
Barclays Capital today reaffirms its equal weight investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and raised its price target to 2350p (from 2200p).
Story provided by StockMarketWire.com
Broker Forecasts data provided by www.sharesmagazine.co.u
07-Aug-2020 07:35 AM
Generic pharmaceuticals company Hikma Pharmaceuticals upgraded its outlook on its injectable business after first-half results came in ahead of its expectations on increased demand for Covid-19-related products.
For the six months ended 30 June, pre-tax
30-Jul-2020 08:30 AM
Peel Hunt today reaffirms its buy investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and raised its price target to 2860p (from 2380p).
Story provided by StockMarketWire.com
Broker Forecasts data provided by www.sharesmagazine.co.uk...
07-Jul-2020 11:00 AM
Morgan Stanley today upgrades its investment rating on Hikma Pharmaceuticals PLC (LON:HIK) to overweight (from equal weight) and raised its price target to 2600p (from 2200p).
Story provided by StockMarketWire.com
Broker Forecasts data provided by www.s
30-Apr-2020 07:45 AM
Hikma Pharmaceuticals maintained its guidance and said it had made a 'strong start' to the year despite the challenging market conditions owing to the Covid-19 crisis.
The company reiterating its guidance for global injectables revenue growth
28-Apr-2020 11:30 AM
Barclays Capital today reaffirms its equal weight investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and raised its price target to 2200p (from 1950p).
Story provided by StockMarketWire.com
Broker Forecasts data provided by www.sharesmagazine.co.u
24-Apr-2020 10:40 AM
Goldman Sachs today downgrades its investment rating on Hikma Pharmaceuticals PLC (LON:HIK) to neutral (from buy) and raised its price target to 2400p (from 2200p).
Story provided by StockMarketWire.com
Broker Forecasts data provided by www.sharesmagaz
07-Apr-2020 10:30 AM
Peel Hunt today upgrades its investment rating on Hikma Pharmaceuticals PLC (LON:HIK) to buy (from buy).
Story provided by StockMarketWire.com
Broker Forecasts data provided by www.sharesmagazine.co.uk...
03-Apr-2020 09:50 AM
Citigroup today reaffirms its buy investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and raised its price target to 2500p (from 2150p).
Story provided by StockMarketWire.com
Broker Forecasts data provided by www.sharesmagazine.co.uk...
02-Apr-2020 10:20 AM
Peel Hunt today upgrades its investment rating on Hikma Pharmaceuticals PLC (LON:HIK) to buy (from hold) and raised its price target to 2380p (from 1990p).
Story provided by StockMarketWire.com
Broker Forecasts data provided by www.sharesmagazine.co.uk.
31-Mar-2020 09:00 AM
Generic pharmaceutical company Hikma Pharmaceuticals said a U.S. ruled that patents covering Amarin's heart drug were invalid, paving the way for the company to sell generic versions of the drug.
Hikma said it was working closely with the U.S. Food
12-Mar-2020 12:50 PM
Jefferies International today reaffirms its buy investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and raised its price target to 2390p (from 2300p).
Story provided by StockMarketWire.com
Broker Forecasts data provided by www.sharesmagazine.co.uk.
10-Mar-2020 12:50 PM
Citigroup today upgrades its investment rating on Hikma Pharmaceuticals PLC (LON:HIK) to buy (from neutral) and raised its price target to 2150p (from 1980p).
Story provided by StockMarketWire.com
Broker Forecasts data provided by www.sharesmagazine.co.
02-Mar-2020 01:50 PM
Barclays Capital today reaffirms its equal weight investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and raised its price target to 1950p (from 1900p).
Story provided by StockMarketWire.com
Broker Forecasts data provided by www.sharesmagazine.co.u